Amdocs Gross Profit vs Research and Development Expense Analysis

DOX
 Stock
  

USD 88.95  1.36  1.55%   

Amdocs financial indicator trend analysis is way more than just evaluating Amdocs Limited prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amdocs Limited is a good investment. Please check the relationship between Amdocs Gross Profit and its Research and Development Expense accounts. Continue to Investing Opportunities.

Gross Profit vs Research and Development Expense

Gross Profit vs Research and Development Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amdocs Limited Gross Profit account and Research and Development Expense. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Amdocs' Gross Profit and Research and Development Expense is 0.97. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Research and Development Expense in the same time period over historical financial statements of Amdocs Limited, assuming nothing else is changed. The correlation between historical values of Amdocs' Gross Profit and Research and Development Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Amdocs Limited are associated (or correlated) with its Research and Development Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research and Development Expense has no effect on the direction of Gross Profit i.e., Amdocs' Gross Profit and Research and Development Expense go up and down completely randomly.

Correlation Coefficient

0.97
Relationship DirectionPositive 
Relationship StrengthVery Strong

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Amdocs Limited minus its cost of goods sold. It is profit before Amdocs operating expenses, interest payments and taxes. Gross profit is also known as gross margin. Aggregate revenue Revenues less cost of revenue [CoR] directly attributable to the revenue generation activity.

Research and Development Expense

A component of Operating Expenses representing the aggregate costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service.
Most indicators from Amdocs fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amdocs Limited current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Investing Opportunities.Amdocs Net Cash Flow Business Acquisitions and Disposals is fairly stable at the moment as compared to the past year. Amdocs reported Net Cash Flow Business Acquisitions and Disposals of 168.24 Million in 2021. Enterprise Value over EBIT is likely to rise to 15.21 in 2022, whereas Selling General and Administrative Expense is likely to drop slightly above 557.8 M in 2022.
 2019 2020 2021 2022 (projected)
Consolidated Income497.84 M688.37 M791.63 M673.75 M
Direct Expenses2.76 B2.81 B2.53 B2.34 B

Amdocs fundamental ratios Correlations

0.150.24-0.550.44-0.80.71-0.380.06-0.220.330.550.160.310.050.030.290.79-0.66-0.79
0.15-0.29-0.66-0.15-0.550.10.090.04-0.26-0.21-0.11-0.33-0.18-0.26-0.05-0.160.150.25-0.12
0.24-0.29-0.30.96-0.30.66-0.9-0.870.740.930.930.980.80.940.860.960.7-0.6-0.49
-0.55-0.66-0.3-0.50.94-0.70.460.340.01-0.33-0.53-0.24-0.21-0.26-0.33-0.44-0.680.160.73
0.44-0.150.96-0.5-0.530.8-0.92-0.80.620.890.980.940.750.890.810.960.81-0.63-0.65
-0.8-0.55-0.30.94-0.53-0.790.480.220.1-0.37-0.6-0.23-0.28-0.2-0.25-0.43-0.80.380.81
0.710.10.66-0.70.8-0.79-0.75-0.480.110.710.820.580.450.580.50.740.87-0.58-0.79
-0.380.09-0.90.46-0.920.48-0.750.85-0.67-0.86-0.88-0.87-0.69-0.86-0.91-0.91-0.780.510.56
0.060.04-0.870.34-0.80.22-0.480.85-0.85-0.85-0.74-0.84-0.73-0.87-0.96-0.83-0.550.320.31
-0.22-0.260.740.010.620.10.11-0.67-0.850.620.560.780.720.730.860.640.26-0.28-0.08
0.33-0.210.93-0.330.89-0.370.71-0.86-0.850.620.910.840.860.810.790.860.8-0.69-0.59
0.55-0.110.93-0.530.98-0.60.82-0.88-0.740.560.910.870.830.810.740.910.88-0.73-0.75
0.16-0.330.98-0.240.94-0.230.58-0.87-0.840.780.840.870.730.960.860.950.59-0.51-0.39
0.31-0.180.8-0.210.75-0.280.45-0.69-0.730.720.860.830.730.630.690.680.71-0.76-0.56
0.05-0.260.94-0.260.89-0.20.58-0.86-0.870.730.810.810.960.630.880.970.52-0.36-0.3
0.03-0.050.86-0.330.81-0.250.5-0.91-0.960.860.790.740.860.690.880.860.54-0.32-0.32
0.29-0.160.96-0.440.96-0.430.74-0.91-0.830.640.860.910.950.680.970.860.71-0.49-0.5
0.790.150.7-0.680.81-0.80.87-0.78-0.550.260.80.880.590.710.520.540.71-0.73-0.85
-0.660.25-0.60.16-0.630.38-0.580.510.32-0.28-0.69-0.73-0.51-0.76-0.36-0.32-0.49-0.730.67
-0.79-0.12-0.490.73-0.650.81-0.790.560.31-0.08-0.59-0.75-0.39-0.56-0.3-0.32-0.5-0.850.67
Click cells to compare fundamentals

Amdocs Account Relationship Matchups

Amdocs fundamental ratios Accounts

201720182019202020212022 (projected)
Receivables971.5 M987.86 M861.03 M866.82 M780.14 M737.36 M
Accounts Payable194.74 M176.51 M110.14 M121.2 M139.38 M156.14 M
Accumulated Other Comprehensive Income18.79 M(32.73 M)(2.55 M)11.66 M13.41 M14.47 M
Total Assets5.35 B5.29 B6.34 B6.51 B7.49 B7.04 B
Current Assets1.72 B1.68 B2.07 B2.07 B1.86 B1.85 B
Assets Non Current3.63 B3.62 B4.27 B4.44 B5.11 B4.59 B
Cash and Equivalents519.22 M471.63 M983.94 M965.59 M869.03 M894.22 M
Cash and Equivalents USD519.22 M471.63 M983.94 M965.59 M869.03 M894.22 M
Deferred Revenue132.41 M118.18 M126.84 M237.37 M272.98 M233.37 M
Shareholders Equity3.45 B3.5 B3.62 B3.59 B4.13 B4.14 B
Shareholders Equity USD3.45 B3.5 B3.62 B3.59 B4.13 B4.14 B
Goodwill and Intangible Assets2.71 B2.67 B2.87 B2.88 B3.31 B3.12 B
Total Liabilities1.86 B1.75 B2.68 B2.88 B3.31 B2.86 B
Current Liabilities1.29 B1.21 B1.22 B1.3 B1.5 B1.49 B
Liabilities Non Current560.82 M542.43 M1.46 B1.57 B1.81 B1.95 B
Trade and Non Trade Payables194.74 M176.51 M110.14 M1.01 B1.16 B1.25 B
Property Plant and Equipment Net496.58 M525.31 M903.45 M931.93 M1.07 B1.16 B
Trade and Non Trade Receivables971.5 M987.86 M861.03 M866.82 M996.84 M984.27 M
Accumulated Retained Earnings Deficit4.67 B5.01 B5.34 B5.85 B6.73 B5.93 B
Tax Liabilities219.42 M224.57 M207.51 M258.49 M232.64 M240.95 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Amdocs without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now

   

Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module
Continue to Investing Opportunities. Note that the Amdocs Limited information on this page should be used as a complementary analysis to other Amdocs' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Amdocs Stock analysis

When running Amdocs Limited price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.089
Market Capitalization
10.8 B
Quarterly Revenue Growth YOY
0.088
Return On Assets
0.0605
Return On Equity
0.15
The market value of Amdocs Limited is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine Amdocs value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.